So our inaugural CSO paper- our manifesto- is just out with invitation to all stakeholders to join our movement. @csoncol is all about outcomes that matter to our patients, and how to ensure that our goals are aligned towards improving these outcomes. 1/ https://t.co/OsixGpLCopthelancet.com/journals/lanon…
Here is our mission, vision, and guiding principles. If you agree with our mission, vision, and principles, please do join us at @csoncol 2/ https://t.co/3YVtADR05ncommonsenseoncology.org

Hot off the press!
Do solid tumors undergo spontaneous regression?
Can placebo alone produce response in solid tumors?
We attempt to answer this question in this new study published @eClinicalMed : thelancet.com/journals/eclin… We find an ORR of 2% with placebo mono therapy in advanced solid tumors with pooled ORR of 1% with 95% CI up to 2%. thelancet.com/journals/eclin…

This is going to be a thread of our #MCBS session starting in a couple of minutes at #ESMO22. Follow along for a LIVE tweet-summary of our session! @myESMO @ChernyNathan @VriesElisabeth 1/ First, @ChernyNathan is giving an overview of cancer drugs approved by FDA in last 5 years. For more, read his excellent paper in @NatRevClinOncol published earlier this year. @DianaNrco

Just out in @TheLancetOncol ! Much has been discussed about the FDA accelerated approval system; but what are its consequences for global oncology? This paper with @SuyogCancer and @SirohiBhawna ties my two passions: cancer policy and global oncology. thelancet.com/journals/lanon… Accelerated approval process doesn’t affect cancer care in U.S alone. It has global consequences. Patients in LMICs continue to pay -from their pocket- for cancer drugs with low quality of evidence simply because it’s approved by the FDA. thelancet.com/journals/lanon…

Cancer screening is a double edge sword. Better technology simply could mean we are able to pick up smaller tumors that may not have needed treatment. Important data from Taiwan on lung cancer screening. jamanetwork.com/journals/jamai… What does this picture say?

I’m officially starting my faculty career in academic oncology as an Associate Professor @queensoncology @QueensUHealth from June 1st, 2021. I’m super excited about it, and very thankful to everyone who has had a role in making this happen. This is a twitter thread of gratitude. First of all, I’m extremely thankful to my mentor Chris Booth. Honestly, Chris is the reason I moved to Queen’s. He has not only supported me in my career but has also been a great friend and advisor. I feel lucky to be working with him.

It was my pleasure sharing some thoughts on communication skills in oncology with the participants of @ecancer #Kolkata21 meeting today morning. The video is already available to watch for those interested: ecancer.org/en/video/9670-… With special thanks to @ChernyNathan @scottrberry and @ramsedhom for providing me advice/thoughts/slides to make this talk possible. I myself learned a lot in this process.

Published just now in @ASCO_pubs JCO Global Oncology. The FIRST report of a population-based cancer registry from Nepal. It felt very meaningful to contribute to this #cancergroundshot project. ascopubs.org/doi/full/10.12… #globaloncology For the first time, we now have official data on the commonest cancers in Kathmandu by incidence and mortality in different subgroups of population. ascopubs.org/doi/full/10.12…

Very happy to see this announcement today from @FDAOncology . Early approval based on surrogate and appropriate action upon failure to confirm clinical benefit in confirmatory trial is the mandate of accelerated approval. fda.gov/news-events/fd… Several of our works @PORTAL_Research have previously highlighted that this follow-through has not been happening. Failure to act when drugs fail to improve clinical benefit in confirmatory trials breaks the social compromise of AA. I will share 2 imp papers in this regard.

This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/ This was my first publication ever. A correspondence to @TheLancetOncol in 2014 about cancer care and research in Nepal with @Poudyalbishesh : thelancet.com/journals/lanon…

Seems like this is the time to look back upon your year. Here’s a thread on my tweets from 2019 that I’d like to share again with the new followers. No particular order. Here’s the first one: medscape.com/viewarticle/91… I learned a lot by reading all the comments to this piece.

https://twitter.com/oncology_bg/status/1176981211396431872

The next tweet is a little sad because it’s true:

https://twitter.com/oncology_bg/status/1174419012039663621?s=21

https://twitter.com/oncology_bg/status/1174419012039663621

There's a great coverage today in @Medscape of our latest @bmj_latest paper. Unfortunately, I'll have to disagree with these comments from an expert which I find disrespectful. RANTORIAL ahead. medscape.com/viewarticle/90… All 4 authors in our @bmj_latest paper are medical oncologists. It's our daily job to talk to patients about benefits and side effects of cancer drugs. What's the basis for suggesting that we didn't talk to patients? The no. of medical oncologists in the world is ..surprise. >1!